SGLT2 inhibitor for brain protection after acute stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a medicine called an SGLT2 inhibitor, which is usually used for diabetes, can help protect the brain and improve recovery when given soon after a stroke. It is for people who had a stroke within the last 3 days and have moderate to severe symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stroke within the last 3 days.
- Your stroke symptoms are moderate to severe (measured by a standard scale).
- You were able to do your usual daily activities before the stroke (no major disability).
- You do not have type 1 diabetes, heart failure, or severe kidney or liver problems.
- You have not taken an SGLT2 inhibitor in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called a GLP-1 receptor agonist (a type of drug used for diabetes) can improve recovery after a major stroke that was treated with a procedure to remove the blood clot. The goal is to see if this drug helps reduce further brain damage and improve outcomes.
This trial tests whether a drug called urinary kallidinogenase can help people who have had a stroke caused by a blocked artery in the brain. The drug is given within 48 hours of the stroke, and the study hopes to see if it improves recovery and reduces disability.
This trial tests a drug called urinary kallidinogenase in people who have had a stroke and also have type 2 diabetes. The drug may help improve recovery after a stroke.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This Phase 2 trial tests whether an SGLT2 medicine started after a first STEMI heart attack can reduce ongoing heart muscle injury and scarring. It may help people who, based on heart imaging, have larger infarcts and ongoing microvascular damage.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.